ketamine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1523 6740-88-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ketamine
  • narketan
  • (+/-)-Ketamine
  • ketamine hydrochloride
  • ketamine HCl
A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
  • Molecular weight: 237.73
  • Formula: C13H16ClNO
  • CLOGP: 2.93
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 1
  • TPSA: 29.10
  • ALOGS: -3.71
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 200 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 4 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 8.41 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 20 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 2.90 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 19 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.47 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.80 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Feb. 19, 1970 FDA PAR STERILE PRODUCTS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 463.65 22.38 162 8655 19993 50576314
Dilatation intrahepatic duct acquired 143.38 22.38 31 8786 614 50595693
Bronchospasm 131.38 22.38 60 8757 14794 50581513
Propofol infusion syndrome 127.24 22.38 29 8788 737 50595570
Body tinea 126.05 22.38 32 8785 1295 50595012
Hydronephrosis 116.88 22.38 47 8770 8494 50587813
Inhibitory drug interaction 105.16 22.38 31 8786 2202 50594105
Infection susceptibility increased 104.95 22.38 32 8785 2552 50593755
Mitochondrial DNA mutation 102.65 22.38 20 8797 230 50596077
Drug ineffective for unapproved indication 102.63 22.38 57 8760 21224 50575083
Intra-abdominal pressure increased 99.06 22.38 19 8798 200 50596107
Pneumatosis 91.79 22.38 20 8797 411 50595896
Biliary dilatation 91.26 22.38 27 8790 1942 50594365
Glucose tolerance impaired 83.52 22.38 32 8785 5086 50591221
Sterile pyuria 82.14 22.38 12 8805 15 50596292
Impaired quality of life 81.73 22.38 33 8784 6023 50590284
Multiple-drug resistance 81.30 22.38 28 8789 3286 50593021
Delirium 80.98 22.38 61 8756 38131 50558176
Blood lactic acid increased 80.80 22.38 32 8785 5553 50590754
Hypercapnia 79.35 22.38 30 8787 4597 50591710
Respiratory depression 77.25 22.38 39 8778 11971 50584336
Oesophageal spasm 74.69 22.38 24 8793 2272 50594035
Necrosis ischaemic 74.57 22.38 19 8798 780 50595527
Blood pH decreased 73.11 22.38 24 8793 2431 50593876
Off label use 71.30 22.38 212 8605 474214 50122093
Status epilepticus 70.40 22.38 38 8779 13368 50582939
Drug ineffective 70.06 22.38 304 8513 819029 49777278
Oesophageal pain 70.00 22.38 24 8793 2778 50593529
Reduced bladder capacity 68.90 22.38 9 8808 0 50596307
Blood gases abnormal 68.61 22.38 17 8800 622 50595685
Intestinal ischaemia 68.36 22.38 30 8787 6727 50589580
Hypotension 67.33 22.38 135 8682 235334 50360973
Hyperaesthesia 65.97 22.38 31 8786 8142 50588165
Gene mutation 65.83 22.38 19 8798 1252 50595055
Unwanted awareness during anaesthesia 65.04 22.38 14 8803 271 50596036
Cardio-respiratory arrest 64.57 22.38 62 8755 53830 50542477
Cardiac arrest 64.30 22.38 76 8741 83575 50512732
Purpura 63.20 22.38 32 8785 9879 50586428
Drug abuse 62.72 22.38 64 8753 59782 50536525
Arthralgia 60.93 22.38 4 8813 438698 50157609
Intestinal infarction 60.86 22.38 17 8800 995 50595312
Bone density decreased 59.85 22.38 32 8785 11043 50585264
Anaphylactic reaction 58.82 22.38 59 8758 53996 50542311
Poor quality sleep 57.64 22.38 36 8781 16610 50579697
Bladder hypertrophy 57.06 22.38 12 8805 207 50596100
Venoocclusive liver disease 56.74 22.38 23 8794 4238 50592069
Impaired work ability 56.25 22.38 33 8784 13607 50582700
Shock 55.24 22.38 38 8779 20612 50575695
Local anaesthetic systemic toxicity 54.40 22.38 14 8803 598 50595709
Airway peak pressure increased 53.50 22.38 12 8805 283 50596024
Systemic inflammatory response syndrome 52.97 22.38 23 8794 5026 50591281
Respiratory acidosis 52.18 22.38 24 8793 6004 50590303
Contracted bladder 51.09 22.38 7 8810 3 50596304
Lung hyperinflation 50.37 22.38 15 8802 1103 50595204
PCO2 increased 50.04 22.38 15 8802 1128 50595179
Ultrasound ovary abnormal 47.61 22.38 9 8808 87 50596220
Anaphylactoid shock 47.26 22.38 11 8806 307 50596000
Hyperlipidaemia 46.34 22.38 32 8785 17458 50578849
Hepatocellular injury 45.36 22.38 37 8780 25910 50570397
Agitation 45.19 22.38 51 8766 53333 50542974
Perforation 43.71 22.38 13 8804 951 50595356
Oral herpes 43.67 22.38 33 8784 20692 50575615
PO2 decreased 43.14 22.38 14 8803 1367 50594940
Biliary tract disorder 42.90 22.38 12 8805 706 50595601
Lymphoedema 42.77 22.38 24 8793 9098 50587209
Sedation 42.01 22.38 38 8779 30572 50565735
Tonic clonic movements 40.52 22.38 13 8804 1224 50595083
Lower urinary tract symptoms 40.42 22.38 7 8810 39 50596268
Hepatotoxicity 39.75 22.38 35 8782 27191 50569116
Skin disorder 39.37 22.38 33 8784 23997 50572310
Ureteral polyp 38.28 22.38 5 8812 0 50596307
Cystitis ulcerative 38.28 22.38 5 8812 0 50596307
Metabolic acidosis 37.92 22.38 40 8777 38785 50557522
Blood bicarbonate decreased 37.28 22.38 15 8802 2710 50593597
Status asthmaticus 36.76 22.38 11 8806 822 50595485
Diastolic hypotension 35.73 22.38 7 8810 83 50596224
Renal infarct 35.34 22.38 12 8805 1348 50594959
Hallucination 35.17 22.38 42 8775 46615 50549692
Cystitis 35.05 22.38 41 8776 44523 50551784
Stress cardiomyopathy 34.95 22.38 20 8797 7867 50588440
Intensive care unit acquired weakness 34.24 22.38 10 8807 687 50595620
Reversible cerebral vasoconstriction syndrome 33.68 22.38 13 8804 2106 50594201
Headache 33.24 22.38 24 8793 506511 50089796
Tachycardia 33.07 22.38 61 8756 99702 50496605
Bladder necrosis 32.16 22.38 5 8812 12 50596295
Post procedural stroke 32.03 22.38 6 8811 55 50596252
Left ventricular hypertrophy 31.93 22.38 16 8801 4829 50591478
Cystitis interstitial 31.71 22.38 11 8806 1318 50594989
Ureteric stenosis 31.53 22.38 9 8808 570 50595737
Bladder disorder 30.44 22.38 18 8799 7525 50588782
Mucocutaneous haemorrhage 29.97 22.38 6 8811 80 50596227
Oxygen saturation decreased 29.76 22.38 49 8768 73199 50523108
Abdominal discomfort 29.64 22.38 3 8814 231638 50364669
Nausea 29.16 22.38 49 8768 705349 49890958
Blood creatine phosphokinase increased 29.06 22.38 29 8788 26338 50569969
Bradypnoea 29.01 22.38 13 8804 3061 50593246
Tachyphylaxis 28.22 22.38 7 8810 257 50596050
Cholestasis 28.11 22.38 28 8789 25373 50570934
Intensive care unit delirium 27.30 22.38 5 8812 40 50596267
Cyanosis 27.27 22.38 22 8795 15162 50581145
Haematuria 26.09 22.38 27 8790 25586 50570721
Sleep apnoea syndrome 25.84 22.38 26 8791 23842 50572465
Drug tolerance 25.82 22.38 14 8803 4962 50591345
Tinnitus 25.73 22.38 28 8789 28104 50568203
Urinary tract disorder 25.48 22.38 11 8806 2369 50593938
Immune thrombocytopenia 25.07 22.38 17 8800 9000 50587307
Alopecia 25.00 22.38 6 8811 245041 50351266
Rheumatoid arthritis 24.96 22.38 3 8814 202547 50393760
Euthyroid sick syndrome 24.82 22.38 5 8812 69 50596238
Cardiomegaly 24.28 22.38 21 8796 15924 50580383
Drug abuser 23.66 22.38 11 8806 2817 50593490
Peripheral swelling 23.16 22.38 4 8813 205932 50390375
Platelet disorder 23.02 22.38 9 8808 1508 50594799
Bladder neck obstruction 22.97 22.38 3 8814 0 50596307
Drug use disorder 22.79 22.38 11 8806 3061 50593246
Ureteral disorder 22.53 22.38 6 8811 293 50596014

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 334.15 21.71 126 7379 13210 29553812
Drug abuse 159.63 21.71 144 7361 79739 29487283
Cystitis ulcerative 131.05 21.71 18 7487 0 29567022
Drug ineffective 117.85 21.71 273 7232 362897 29204125
Hydronephrosis 92.84 21.71 45 7460 8685 29558337
Anaphylactic reaction 89.35 21.71 66 7439 27507 29539515
Hypotension 86.94 21.71 167 7338 194187 29372835
Sedation 80.79 21.71 52 7453 17353 29549669
Biopsy bladder abnormal 72.80 21.71 10 7495 0 29567022
Delirium 68.77 21.71 66 7439 39331 29527691
Bradycardia 65.65 21.71 82 7423 65547 29501475
Cystitis 65.58 21.71 35 7470 8257 29558765
Reduced bladder capacity 65.52 21.71 9 7496 0 29567022
Drug screen positive 63.97 21.71 27 7478 3774 29563248
Bronchospasm 63.43 21.71 36 7469 9573 29557449
Nightmare 62.79 21.71 38 7467 11379 29555643
Cystitis interstitial 62.05 21.71 13 7492 147 29566875
Respiratory depression 61.75 21.71 40 7465 13483 29553539
Off label use 56.81 21.71 186 7319 300614 29266408
Contracted bladder 51.32 21.71 8 7497 11 29567011
Pulseless electrical activity 50.43 21.71 27 7478 6407 29560615
Behaviour disorder 48.84 21.71 22 7483 3594 29563428
Toxicity to various agents 48.78 21.71 124 7381 173537 29393485
Diabetes insipidus 46.74 21.71 19 7486 2415 29564607
Cardiac arrest 46.25 21.71 80 7425 85511 29481511
Cholestasis 46.09 21.71 42 7463 23420 29543602
Drug dependence 42.08 21.71 38 7467 20943 29546079
Biliary dilatation 38.36 21.71 12 7493 711 29566311
Agitation 37.39 21.71 55 7450 51249 29515773
Diarrhoea 35.90 21.71 20 7485 332678 29234344
Accidental death 35.49 21.71 15 7490 2103 29564919
Drug ineffective for unapproved indication 35.10 21.71 29 7476 14185 29552837
Drug use disorder 34.45 21.71 17 7488 3405 29563617
Nephrolithiasis 34.25 21.71 37 7468 25297 29541725
Hyperaesthesia 34.23 21.71 17 7488 3452 29563570
Delayed recovery from anaesthesia 34.22 21.71 11 7494 712 29566310
Biliary tract disorder 33.48 21.71 11 7494 763 29566259
Tachycardia 33.13 21.71 63 7442 72347 29494675
Metabolic acidosis 32.82 21.71 44 7461 37618 29529404
Wolff-Parkinson-White syndrome 32.34 21.71 8 7497 197 29566825
Anaphylactoid shock 32.17 21.71 9 7496 361 29566661
Hyperammonaemia 31.51 21.71 19 7486 5644 29561378
Bladder disorder 31.50 21.71 15 7490 2779 29564243
Airway complication of anaesthesia 29.50 21.71 7 7498 144 29566878
Ureteral polyp 29.12 21.71 4 7501 0 29567022
Drug tolerance 28.76 21.71 13 7492 2140 29564882
Abdominal compartment syndrome 28.71 21.71 10 7495 829 29566193
Axillary pain 28.68 21.71 8 7497 317 29566705
Cholangiolitis 28.36 21.71 5 7500 20 29567002
Laryngospasm 28.00 21.71 11 7494 1279 29565743
Haematuria traumatic 27.93 21.71 7 7498 182 29566840
Brief psychotic disorder with marked stressors 27.65 21.71 7 7498 190 29566832
Fatigue 27.60 21.71 24 7481 316797 29250225
Neonatal hypoxia 27.39 21.71 8 7497 375 29566647
Urinary tract disorder 26.87 21.71 12 7493 1920 29565102
Multiple-drug resistance 26.78 21.71 15 7490 3885 29563137
Substance abuse 25.98 21.71 18 7487 6769 29560253
Dyspnoea 25.83 21.71 27 7478 326705 29240317
Pneumonia 25.83 21.71 26 7479 320146 29246876
Product use in unapproved indication 25.31 21.71 63 7442 86812 29480210
Hypoxia 25.18 21.71 44 7461 47335 29519687
Diastolic hypertension 24.70 21.71 5 7500 47 29566975
Hypercapnia 24.69 21.71 14 7491 3712 29563310
Sedation complication 24.59 21.71 10 7495 1272 29565750
Complication of device removal 24.42 21.71 5 7500 50 29566972
Anaesthetic complication neurological 24.17 21.71 7 7498 318 29566704
Intensive care unit acquired weakness 23.89 21.71 9 7496 934 29566088
Bladder hypertrophy 23.81 21.71 8 7497 595 29566427
Upper airway obstruction 23.64 21.71 8 7497 608 29566414
Transcranial electrical motor evoked potential monitoring abnormal 23.58 21.71 4 7501 12 29567010
Neutropenia 23.25 21.71 3 7502 131708 29435314
Somnolence 23.15 21.71 64 7441 93891 29473131
Unmasking of previously unidentified disease 22.39 21.71 8 7497 715 29566307
Muscle contracture 22.13 21.71 9 7496 1144 29565878

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 768.07 19.23 286 15508 30042 64452896
Hydronephrosis 210.27 19.23 91 15703 14034 64468904
Drug abuse 208.32 19.23 206 15588 132168 64350770
Bronchospasm 181.70 19.23 94 15700 21588 64461350
Drug ineffective 172.96 19.23 522 15272 839725 63643213
Cystitis ulcerative 168.26 19.23 23 15771 0 64482938
Hypotension 135.74 19.23 292 15502 380682 64102256
Anaphylactic reaction 134.96 19.23 121 15673 68543 64414395
Reduced bladder capacity 131.68 19.23 18 15776 0 64482938
Propofol infusion syndrome 131.32 19.23 37 15757 1580 64481358
Biliary dilatation 127.42 19.23 39 15755 2229 64480709
Drug ineffective for unapproved indication 120.59 19.23 82 15712 31051 64451887
Dilatation intrahepatic duct acquired 115.12 19.23 28 15766 666 64482272
Delirium 112.98 19.23 110 15684 69084 64413854
Body tinea 111.45 19.23 31 15763 1262 64481676
Off label use 110.25 19.23 372 15422 632434 63850504
Respiratory depression 108.44 19.23 69 15725 23374 64459564
Cardiac arrest 102.19 19.23 155 15639 153909 64329029
Mitochondrial DNA mutation 95.15 19.23 20 15774 239 64482699
Hypercapnia 93.43 19.23 43 15751 7651 64475287
Contracted bladder 92.72 19.23 14 15780 14 64482924
Intra-abdominal pressure increased 90.32 19.23 19 15775 228 64482710
Infection susceptibility increased 88.68 19.23 31 15763 2695 64480243
Hyperaesthesia 88.45 19.23 45 15749 9969 64472969
Arthralgia 88.26 19.23 5 15789 442255 64040683
Sedation 87.28 19.23 76 15718 41386 64441552
Sterile pyuria 86.01 19.23 15 15779 58 64482880
Cystitis 85.38 19.23 76 15718 42599 64440339
Cystitis interstitial 83.36 19.23 24 15770 1108 64481830
Pneumatosis 81.65 19.23 22 15772 794 64482144
Biopsy bladder abnormal 80.47 19.23 11 15783 0 64482938
Bladder hypertrophy 79.66 19.23 20 15774 544 64482394
Inhibitory drug interaction 76.51 19.23 30 15764 3597 64479341
Agitation 74.90 19.23 100 15694 88267 64394671
Multiple-drug resistance 74.79 19.23 35 15759 6467 64476471
Anaphylactoid shock 73.90 19.23 20 15774 734 64482204
Oesophageal spasm 71.85 19.23 26 15768 2499 64480439
Cholestasis 68.87 19.23 69 15725 44803 64438135
Cardio-respiratory arrest 68.03 19.23 101 15693 98292 64384646
Metabolic acidosis 65.88 19.23 84 15710 70874 64412064
Ureteral polyp 65.84 19.23 9 15785 0 64482938
Impaired quality of life 65.79 19.23 32 15762 6439 64476499
Oesophageal pain 65.36 19.23 26 15768 3237 64479701
Blood lactic acid increased 64.60 19.23 37 15757 10364 64472574
Necrosis ischaemic 64.26 19.23 19 15775 964 64481974
Respiratory acidosis 63.74 19.23 36 15758 9819 64473119
Diabetes insipidus 63.58 19.23 28 15766 4493 64478445
Bladder disorder 63.10 19.23 33 15761 7734 64475204
Glucose tolerance impaired 62.92 19.23 31 15763 6412 64476526
Drug screen positive 60.26 19.23 29 15765 5700 64477238
Tachycardia 59.25 19.23 120 15674 149459 64333479
Shock 59.04 19.23 59 15735 38181 64444757
Status epilepticus 58.72 19.23 46 15748 21617 64461321
Laryngospasm 57.22 19.23 24 15770 3421 64479517
Headache 56.06 19.23 30 15764 529437 63953501
Intestinal ischaemia 55.91 19.23 35 15759 11514 64471424
Drug dependence 54.41 19.23 53 15741 33259 64449679
Lower urinary tract symptoms 53.95 19.23 12 15782 190 64482748
Intensive care unit acquired weakness 53.73 19.23 19 15775 1708 64481230
Airway peak pressure increased 52.86 19.23 13 15781 324 64482614
Diarrhoea 51.43 19.23 61 15733 722643 63760295
Blood gases abnormal 51.40 19.23 16 15778 967 64481971
Intestinal infarction 51.07 19.23 17 15777 1274 64481664
Hepatocellular injury 50.84 19.23 59 15735 45176 64437762
Bradycardia 50.61 19.23 98 15696 118121 64364817
Bone density decreased 50.30 19.23 31 15763 9921 64473017
Gene mutation 50.27 19.23 19 15775 2063 64480875
Biliary tract disorder 49.80 19.23 17 15777 1376 64481562
Urinary tract disorder 49.07 19.23 21 15773 3145 64479793
Local anaesthetic systemic toxicity 48.12 19.23 14 15780 671 64482267
Drug use disorder 47.13 19.23 25 15769 6029 64476909
Poor quality sleep 46.58 19.23 38 15756 18913 64464025
Behaviour disorder 45.16 19.23 22 15772 4440 64478498
Unwanted awareness during anaesthesia 44.74 19.23 11 15783 274 64482664
Ultrasound ovary abnormal 44.56 19.23 9 15785 87 64482851
Lung hyperinflation 43.64 19.23 16 15778 1596 64481342
Status asthmaticus 43.34 19.23 14 15780 954 64481984
Blood pH decreased 42.45 19.23 21 15773 4381 64478557
Joint swelling 41.22 19.23 3 15791 215379 64267559
Dyspnoea 40.89 19.23 71 15723 718603 63764335
Airway complication of anaesthesia 40.71 19.23 11 15783 401 64482537
Impaired work ability 40.56 19.23 32 15762 15187 64467751
Ureteric stenosis 39.66 19.23 14 15780 1252 64481686
PCO2 increased 39.48 19.23 15 15779 1652 64481286
Pulseless electrical activity 38.80 19.23 29 15765 12710 64470228
Drug tolerance 38.73 19.23 22 15772 6063 64476875
Ureteral disorder 38.50 19.23 11 15783 494 64482444
Lymphoedema 38.12 19.23 26 15768 9879 64473059
Hypoxia 37.62 19.23 73 15721 88076 64394862
Nightmare 37.31 19.23 35 15759 20958 64461980
Perforation 37.13 19.23 13 15781 1135 64481803
Tonic clonic movements 36.91 19.23 15 15779 1974 64480964
Hallucination 35.71 19.23 64 15730 72724 64410214
Venoocclusive liver disease 35.51 19.23 25 15769 9990 64472948
Purpura 35.04 19.23 31 15763 17215 64465723
Sedation complication 34.76 19.23 25 15769 10329 64472609
Drug abuser 34.30 19.23 20 15774 5788 64477150
Accidental death 33.65 19.23 17 15777 3708 64479230
Delayed recovery from anaesthesia 33.50 19.23 13 15781 1515 64481423
Anaesthetic complication neurological 33.30 19.23 10 15784 535 64482403
Systemic inflammatory response syndrome 32.74 19.23 24 15770 10211 64472727
Asthenia 32.70 19.23 34 15760 428010 64054928
Stress cardiomyopathy 32.57 19.23 23 15771 9234 64473704
Hepatotoxicity 31.97 19.23 44 15750 39918 64443020
Nasopharyngitis 31.76 19.23 5 15789 196068 64286870
Product use in unapproved indication 31.50 19.23 105 15689 176513 64306425
Dissociative disorder 31.33 19.23 9 15785 412 64482526
Abdominal discomfort 31.05 19.23 4 15790 182318 64300620
Wolff-Parkinson-White syndrome 30.61 19.23 8 15786 256 64482682
Oral herpes 30.24 19.23 32 15762 22120 64460818
Diastolic hypotension 30.12 19.23 7 15787 136 64482802
Fall 29.75 19.23 35 15759 416791 64066147
Transcranial electrical motor evoked potential monitoring abnormal 29.40 19.23 5 15789 16 64482922
PO2 decreased 29.34 19.23 14 15780 2699 64480239
Neutropenia 29.33 19.23 11 15783 239613 64243325
Bladder necrosis 29.17 19.23 5 15789 17 64482921
Type I hypersensitivity 28.50 19.23 15 15779 3559 64479379
Peripheral swelling 28.42 19.23 8 15786 209145 64273793
Circulatory collapse 28.28 19.23 38 15756 33694 64449244
Back pain 28.18 19.23 13 15781 250158 64232780
Haematuria traumatic 28.14 19.23 7 15787 183 64482755
Cough 27.92 19.23 20 15774 302128 64180810
Cholangiolitis 27.62 19.23 5 15789 25 64482913
Hyperlipidaemia 27.55 19.23 31 15763 22945 64459993
Sleep apnoea syndrome 27.17 19.23 35 15759 29797 64453141
Chest pain 26.99 19.23 12 15782 235968 64246970
Oedema peripheral 26.86 19.23 9 15785 210308 64272630
Pyuria 26.69 19.23 12 15782 2021 64480917
Macroglossia 26.67 19.23 10 15784 1062 64481876
Dehydration 26.45 19.23 10 15784 216753 64266185
Post procedural stroke 26.30 19.23 6 15788 107 64482831
Swelling 26.14 19.23 4 15790 160214 64322724
Oxygen saturation decreased 25.97 19.23 71 15723 107105 64375833
Paralysis 25.90 19.23 22 15772 11573 64471365
Brief psychotic disorder with marked stressors 25.68 19.23 7 15787 264 64482674
Pain in extremity 25.55 19.23 22 15772 303063 64179875
Miosis 25.28 19.23 23 15771 13243 64469695
Alopecia 25.15 19.23 5 15789 165685 64317253
Upper airway obstruction 25.11 19.23 10 15784 1248 64481690
Intensive care unit delirium 25.07 19.23 5 15789 45 64482893
Reversible cerebral vasoconstriction syndrome 25.07 19.23 12 15782 2330 64480608
Renal infarct 24.74 19.23 12 15782 2399 64480539
Skin disorder 24.46 19.23 32 15762 27648 64455290
Blood bicarbonate decreased 24.30 19.23 15 15779 4814 64478124
Decreased appetite 24.22 19.23 20 15774 281269 64201669
Drug intolerance 24.08 19.23 8 15786 187984 64294954
Neuromuscular block prolonged 23.89 19.23 9 15785 968 64481970
Abdominal compartment syndrome 23.89 19.23 10 15784 1418 64481520
Euthyroid sick syndrome 23.84 19.23 5 15789 59 64482879
Apnoea 23.74 19.23 20 15774 10402 64472536
Product dose omission issue 23.73 19.23 9 15785 194738 64288200
Fatigue 23.56 19.23 99 15695 748631 63734307
Mucocutaneous haemorrhage 23.43 19.23 6 15788 177 64482761
Bradypnoea 23.38 19.23 15 15779 5144 64477794
Diastolic hypertension 22.73 19.23 5 15789 75 64482863
Hyperammonaemia 22.55 19.23 19 15775 9885 64473053
Tinnitus 22.09 19.23 34 15760 34099 64448839
Symptom masked 22.07 19.23 9 15785 1195 64481743
Anaemia 21.83 19.23 37 15757 378643 64104295
Cyanosis 21.77 19.23 27 15767 22128 64460810
Urogenital fistula 21.67 19.23 5 15789 94 64482844
Liver function test abnormal 21.54 19.23 46 15748 59355 64423583
Substance abuse 21.51 19.23 18 15776 9274 64473664
Pain 21.48 19.23 67 15727 553444 63929494
Weight decreased 21.45 19.23 23 15771 285716 64197222
Mania 21.30 19.23 23 15771 16263 64466675
Aplastic anaemia 20.60 19.23 21 15773 13899 64469039
Muscle contracture 19.99 19.23 10 15784 2135 64480803
Haematuria 19.86 19.23 45 15749 60426 64422512
Arthropathy 19.77 19.23 3 15791 120964 64361974
Anterograde amnesia 19.75 19.23 7 15787 633 64482305
Pneumonia 19.48 19.23 71 15723 559505 63923433
Haemodynamic instability 19.40 19.23 21 15773 14891 64468047
Infusion related reaction 19.38 19.23 8 15786 164459 64318479
Cystitis noninfective 19.36 19.23 8 15786 1098 64481840
Urinary tract infection 19.28 19.23 17 15777 231579 64251359

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N01AX03 NERVOUS SYSTEM
ANESTHETICS
ANESTHETICS, GENERAL
Other general anesthetics
MeSH PA D000700 Analgesics
MeSH PA D000777 Anesthetics
MeSH PA D000778 Anesthetics, Dissociative
MeSH PA D018686 Anesthetics, Intravenous
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D018691 Excitatory Amino Acid Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
CHEBI has role CHEBI:35703 Xenobiotic
CHEBI has role CHEBI:38877 intravenous anesthetics
CHEBI has role CHEBI:50910 agente neurotoxico
CHEBI has role CHEBI:60643 N-methyl-D-aspartate receptor antagonists
CHEBI has role CHEBI:78298 environmental contaminants
FDA EPC N0000175681 General Anesthetic
FDA PE N0000175975 General Anesthesia

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
General anesthesia indication 50697003
Local anesthesia indication 386761002
Pain off-label use 22253000
Inflammatory disease of mucous membrane off-label use 95361005
Major depressive disorder off-label use 370143000
Delirium contraindication 2776000
Ocular hypertension contraindication 4210003 DOID:9282
Alcoholism contraindication 7200002
Myocardial infarction contraindication 22298006 DOID:5844
Alcohol intoxication contraindication 25702006
Hypertensive disorder contraindication 38341003 DOID:10763
Decreased respiratory function contraindication 80954004
Thyrotoxicosis contraindication 90739004 DOID:7997
Acute disease of cardiovascular system contraindication 128487001
Decompensated cardiac failure contraindication 195111005
Cerebrovascular accident contraindication 230690007
Raised intracranial pressure contraindication 271719001 DOID:9428
Cerebral trauma contraindication 275382005
Impaired cognition contraindication 386806002
Myocardial ischemia contraindication 414795007 DOID:3393
Hypertensive urgency contraindication 443482000
Psychiatric Disturbance contraindication
Cardiac Decompensation contraindication




๐Ÿถ Veterinary Drug Use

SpeciesUseRelation
Cats Restraint Indication
Cats Anesthesia in diagnostic or minor surgical procedures that do not require skeletal muscle relaxation Indication
Primates Restraint Indication
Primates Anesthesia in diagnostic or minor surgical procedures that do not require skeletal muscle relaxation Indication

๐Ÿถ Veterinary products

ProductApplicantIngredients
Ketaset Zoetis Inc. 1
Ketaset, Vetalar Boehringer lngelheim Animal Health USA Inc. 1
Ketaset Plus Zoetis Inc. 3
Ketamine Hydrochloride Injection Cronus Pharma Specialities India Private Limited 1
Ketamine Hydrochloride Injection, USP Elanco US Inc. 1
VetaKet Akorn Animal Health Inc. 1
Ketamine Hydrochloride Injection, USP Dechra Veterinary Products LLC 1
Ketamine HCL Mylan Institutional LLC, a Viatris Company 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.65 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Glutamate [NMDA] receptor Ion channel BLOCKER Ki 6.38 CHEMBL CHEMBL
Glutamate receptor ionotropic AMPA Ion channel OPENER SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Acetylcholine receptor subunit alpha Ion channel IC50 5.31 CHEMBL
Glutamate NMDA receptor Ion channel IC50 6.21 CHEMBL

External reference:

IDSource
4019796 VUID
N0000147885 NUI
D00711 KEGG_DRUG
1867-66-9 SECONDARY_CAS_RN
4018154 VANDF
4019796 VANDF
C0022614 UMLSCUI
CHEBI:6121 CHEBI
CHEMBL742 ChEMBL_ID
DB01221 DRUGBANK_ID
CHEMBL1714 ChEMBL_ID
D007649 MESH_DESCRIPTOR_UI
3821 PUBCHEM_CID
4233 IUPHAR_LIGAND_ID
2156 INN_ID
690G0D6V8H UNII
203184 RXNORM
4944 MMSL
9883 MMSL
d00272 MMSL
001403 NDDF
004581 NDDF
31706007 SNOMEDCT_US
333847008 SNOMEDCT_US
373464007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ketamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9508 INJECTION 50 mg INTRAMUSCULAR ANDA 27 sections
Ketamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9509 INJECTION 100 mg INTRAMUSCULAR ANDA 27 sections
KETALAR HUMAN PRESCRIPTION DRUG LABEL 1 0404-9880 INJECTION 10 mg INTRAVENOUS NDA 17 sections
KETAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0404-9881 INJECTION, SOLUTION, CONCENTRATE 100 mg INTRAMUSCULAR ANDA 19 sections
KETAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0404-9882 INJECTION, SOLUTION, CONCENTRATE 50 mg INTRAMUSCULAR ANDA 14 sections
Ketamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-2051 INJECTION, SOLUTION, CONCENTRATE 100 mg INTRAMUSCULAR ANDA 31 sections
Ketamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-2053 INJECTION, SOLUTION, CONCENTRATE 50 mg INTRAMUSCULAR ANDA 31 sections
Ketalar HUMAN PRESCRIPTION DRUG LABEL 1 42023-113 INJECTION 10 mg INTRAMUSCULAR NDA 27 sections
Ketalar HUMAN PRESCRIPTION DRUG LABEL 1 42023-113 INJECTION 10 mg INTRAMUSCULAR NDA 27 sections
Ketalar HUMAN PRESCRIPTION DRUG LABEL 1 42023-114 INJECTION 50 mg INTRAMUSCULAR NDA 27 sections
Ketalar HUMAN PRESCRIPTION DRUG LABEL 1 42023-114 INJECTION 50 mg INTRAMUSCULAR NDA 27 sections
Ketalar HUMAN PRESCRIPTION DRUG LABEL 1 42023-115 INJECTION 100 mg INTRAMUSCULAR NDA 27 sections
Ketalar HUMAN PRESCRIPTION DRUG LABEL 1 42023-115 INJECTION 100 mg INTRAMUSCULAR NDA 27 sections
KETALAR HUMAN PRESCRIPTION DRUG LABEL 1 52584-037 INJECTION 10 mg INTRAVENOUS NDA 19 sections
KETAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 52584-038 INJECTION, SOLUTION, CONCENTRATE 50 mg INTRAMUSCULAR ANDA 14 sections
KETAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 52584-040 INJECTION, SOLUTION, CONCENTRATE 100 mg INTRAMUSCULAR ANDA 19 sections
KETAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 52584-108 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 14 sections
Ketamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 54868-4399 INJECTION, SOLUTION, CONCENTRATE 50 mg INTRAMUSCULAR ANDA 19 sections
KETAMINE HYDROCHLORIDE Human Prescription Drug Label 1 55150-438 INJECTION 10 mg INTRAVENOUS ANDA 14 sections
KETAMINE HYDROCHLORIDE Human Prescription Drug Label 1 55150-439 INJECTION 50 mg INTRAVENOUS ANDA 14 sections
KETAMINE HYDROCHLORIDE Human Prescription Drug Label 1 55150-440 INJECTION 100 mg INTRAVENOUS ANDA 14 sections
Ketamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 67457-001 INJECTION, SOLUTION 50 mg INTRAVENOUS ANDA 22 sections
Ketamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 67457-108 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 22 sections
Ketamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 67457-181 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 22 sections
Ketamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 70518-2787 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 22 sections
MKO Melt Dose Pack HUMAN PRESCRIPTION DRUG LABEL 3 71384-410 TROCHE 25 mg SUBLINGUAL unapproved drug other 2 sections
MKH Dose Pack HUMAN PRESCRIPTION DRUG LABEL 3 71384-420 TROCHE 25 mg SUBLINGUAL unapproved drug other 2 sections
Ketamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 71872-7258 INJECTION 100 mg INTRAMUSCULAR ANDA 27 sections
Ketamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 72572-320 INJECTION 50 mg INTRAMUSCULAR ANDA 27 sections
Ketamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 72572-321 INJECTION 100 mg INTRAMUSCULAR ANDA 27 sections